需胰岛素治疗的2型糖尿病患者减重手术的临床结局与成本效果分析
基于英国国家减重手术登记库2009–2017年数据,分析2,484例需胰岛素治疗的肥胖2型糖尿病患者,其中1,847例有1年随访。术后1年67%患者不再需要胰岛素,且该比例持续4年。结合文献构建状态转移微观模拟模型,5年时间范围内减重手术相比最佳药物治疗可节省费用。
要点
- 术后1年67%的需胰岛素治疗患者可停用胰岛素,且效果持续4年。
- 胃旁路术胰岛素终止率71.7%高于袖状胃切除术64.5%和可调节胃束带33.6%。
- 5年时间范围内减重手术相比最佳药物治疗总费用更低,具有成本节约效应。
核心结论
- 对于需胰岛素治疗的肥胖2型糖尿病患者,减重手术与术后高胰岛素终止率相关,而胰岛素终止是直接医疗费用总体下降的主要驱动因素。
- 在5年时间范围内,对需胰岛素治疗的肥胖2型糖尿病患者采用减重手术策略对国家医疗服务体系(NHS)而言可节省费用。
研究设计与样本
- 临床数据来自英国国家减重手术登记库(NBSR),纳入2009–2017年接受初次减重手术的需胰岛素治疗的肥胖2型糖尿病患者。
- 共2,484例患者符合纳入标准,其中1,847例有1年随访数据(平均年龄51岁,平均初始BMI 47.2 kg/m2,64%为女性)。
- 结合文献综述数据构建状态转移微观模拟模型,在5年时间范围内评估减重手术对比最佳药物治疗(BMT)的成本效果。
主要发现
- 术后1年67%的患者不再需要胰岛素,且该比例持续4年。
- 胃旁路术(RYGB)胰岛素终止率为71.7%,高于袖状胃切除术(SG)的64.5%(RR 0.92,CI 0.86–0.99)和可调节胃束带(AGB)的33.6%(RR 0.45,CI 0.34–0.60;p < 0.001)。
- 调整总减重百分比和人口学变量后,RYGB与SG的胰岛素终止率相当(RR 0.97,CI 0.90–1.04),AGB终止率最低(RR 0.55,CI 0.40–0.74;p < 0.001)。
- 5年总成本:减重手术组GBP£22,057,BMT组GBP£26,286,增量差异GBP£4,229(减重手术节省)。
关键数值与推荐
- 主要临床结局为术后1年胰岛素终止,报告相对风险(RR)及置信区间(CI)。
- 经济评价主要结局为总成本、总质量调整生命年(QALYs)和增量成本效果比(ICER),支付意愿阈值为GBP£20,000。
临床怎么用
- 对于需胰岛素治疗的肥胖2型糖尿病患者,减重手术可考虑作为实现胰岛素停用和降低直接医疗费用的治疗策略。
- 在5年时间范围内,减重手术对国家医疗服务体系(NHS)具有成本节约效应。
局限性
- NBSR数据集中存在患者失访。
- 经济分析的时间范围仅限于5年。
- 研究反映的是该患者队列当前的药物和手术治疗方案,这些方案可能发生变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although bariatric surgery is well established as an effective treatment for patients with obesity and type 2 diabetes mellitus (T2DM), there exists reluctance to increase its availability for patients with severe T2DM. The aims of this study were to examine the impact of bariatric surgery on T2DM resolution in patients with obesity and T2DM requiring insulin (T2DM-Ins) using data from a national database and to develop a health economic model to evaluate the cost-effectiveness of surgery in this cohort when compared to best medical treatment (BMT). METHODS AND FINDINGS: Clinical data from the National Bariatric Surgical Registry (NBSR), a comprehensive database of bariatric surgery in the United Kingdom, were extracted to analyse outcomes of patients with obesity and T2DM-Ins who underwent primary bariatric surgery between 2009 and 2017. Outcomes for this group were combined with data sourced from a comprehensive literature review in order to develop a state-transition microsimulation model to evaluate cost-effectiveness of bariatric surgery versus BMT for patients over a 5-year time horizon. The main outcome measure for the clinical study was insulin cessation at 1-year post-surgery: relative risks (RR) summarising predictive factors were determined, unadjusted, and after adjusting for variables including age, initial body mass index (BMI), duration of T2DM, and weight loss. Main outcome measures for the economic evaluation were total costs, total quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) at willingness-to-pay threshold of GBP£20,000. A total of 2,484 patients were eligible for inclusion, of which 1,847 had 1-year follow-up data (mean age of 51 years, mean initial BMI 47.2 kg/m2, and 64% female). 67% of patients no longer required insulin at 1-year postoperatively: these rates persisted for 4 years. Roux-en-Y gastric bypass (RYGB) was associated with a higher rate of insulin cessation (71.7%) than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI) 0.86-0.99) and adjustable gastric band (AGB; 33.6%; RR 0.45, CI 0.34-0.60; p < 0.001). When adjusted for percentage total weight loss and demographic variables, insulin cessation following surgery was comparable for RYGB and SG (RR 0.97, CI 0.90-1.04), with AGB having the lowest cessation rates (RR 0.55, CI 0.40-0.74; p < 0.001). Over 5 years, bariatric surgery was cost saving compared to BMT (total cost GBP£22,057 versus GBP£26,286 respectively, incremental difference GBP£4,229). This was due to lower treatment costs as well as reduced diabetes-related complications costs and increased health benefits. Limitations of this study include loss to follow-up of patients within the NBSR dataset and that the time horizon for the economic analysis is limited to 5 years. In addition, the study reflects current medical and surgical treatment regimens for this cohort of patients, which may change. CONCLUSIONS: In this study, we observed that in patients with obesity and T2DM-Ins, bariatric surgery was associated with high rates of postoperative cessation of insulin therapy, which is, in turn, a major driver of overall reductions in direct healthcare cost. Our findings suggest that a strategy utilising bariatric surgery for patients with obesity and T2DM-Ins is cost saving to the national healthcare provider (National Health Service (NHS)) over a 5-year time horizon.
引用
- McGlone ER, Carey I, Veličković V, et al. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses. PLoS Med. 2020. PMID: 33285553. doi:10.1371/journal.pmed.1003228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。